Based on lapatinib, gefitinib and afatinib, PROTACs compound 1/3/4 were respectively developed by linking VHL ligands, exhibiting anti-proliferative activity against breast cancer and lung cancer cells [79]. Here, VHL is linked to breast carcinoma.